PDS Biotechnology (NASDAQ:PDSB) Trading Down 4% – Time to Sell?

Shares of PDS Biotechnology Corporation (NASDAQ:PDSB) dropped 4% during mid-day trading on Thursday . The stock traded as low as $0.8275 and last traded at $0.8721. Approximately 1,023,373 shares changed hands during mid-day trading, an increase of 26% from the average daily volume of 812,523 shares. The stock had previously closed at $0.9085.

Analyst Upgrades and Downgrades

PDSB has been the subject of several analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of PDS Biotechnology in a report on Thursday, January 22nd. B. Riley reduced their price target on PDS Biotechnology from $5.00 to $3.00 and set a “buy” rating for the company in a research report on Tuesday, November 25th. Finally, HC Wainwright boosted their price target on PDS Biotechnology from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $9.00.

PDS Biotechnology Trading Down 4.0%

The company has a debt-to-equity ratio of 1.26, a current ratio of 2.09 and a quick ratio of 2.09. The business has a 50-day simple moving average of $0.89 and a two-hundred day simple moving average of $1.01. The stock has a market cap of $42.72 million, a price-to-earnings ratio of -1.06 and a beta of 1.12.

PDS Biotechnology (NASDAQ:PDSB) last issued its earnings results on Thursday, November 13th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.02. Equities analysts forecast that PDS Biotechnology Corporation will post -1.2 EPS for the current fiscal year.

Institutional Trading of PDS Biotechnology

Several hedge funds and other institutional investors have recently modified their holdings of PDSB. Tempus Wealth Planning LLC lifted its holdings in PDS Biotechnology by 29.3% during the 4th quarter. Tempus Wealth Planning LLC now owns 61,800 shares of the company’s stock worth $48,000 after purchasing an additional 14,000 shares during the last quarter. Watts Gwilliam & Co. LLC bought a new position in PDS Biotechnology in the 2nd quarter valued at about $73,000. Marshall Wace LLP bought a new position in PDS Biotechnology in the second quarter valued at approximately $91,000. Jane Street Group LLC bought a new position in shares of PDS Biotechnology in the 2nd quarter valued at $92,000. Finally, Susquehanna International Group LLP raised its stake in PDS Biotechnology by 603.7% during the third quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock worth $95,000 after acquiring an additional 80,937 shares in the last quarter. Institutional investors own 26.84% of the company’s stock.

PDS Biotechnology Company Profile

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.